Sagimet Biosciences Inc. 今日宣布，其授权合作伙伴歌礼制药在一项开放式三期临床试验中取得了为期52周的积极数据。该试验重点评估了Asc40（Denifanstat）片剂用于中重度痤疮患者的长期安全性。
数据显示，在整个52周的治疗期内，Asc40（Denifanstat）片剂展现出良好的安全性与耐受性特征。这一积极结果为进一步评估该药物治疗痤疮的潜力和长期应用前景提供了有力支持。
Sagimet Biosciences Inc. 今日宣布，其授权合作伙伴歌礼制药在一项开放式三期临床试验中取得了为期52周的积极数据。该试验重点评估了Asc40（Denifanstat）片剂用于中重度痤疮患者的长期安全性。
数据显示，在整个52周的治疗期内，Asc40（Denifanstat）片剂展现出良好的安全性与耐受性特征。这一积极结果为进一步评估该药物治疗痤疮的潜力和长期应用前景提供了有力支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.